{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:58:32Z","timestamp":1794581912165,"version":"4.9.1"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Chronic graft-versus-host disease (cGVHD) is an immune-mediated, heterogeneous, multiorgan complication affecting allogeneic hematopoietic cell transplantation recipients, leading to increased morbidity, mortality, and decline in health-related quality-of-life. Advances in understanding the complex disease pathophysiology, and collaborative efforts lead by the National Institutes of Health to standardize criteria for clinical trials, led to bench-to-bedside efforts resulting in the development of 4 US Food and Drug Administration-approved agents for the treatment steroids-refractory cGVHD since 2017. Despite the remarkable advances in the field of hematopoietic cell transplantation in prevention of cGVHD, and more treatment options, the outcome of patients with moderate-severe cGVHD remains suboptimal. Essential to successful cGVHD management is to recognize the disease at early stages before the onset of irreversible damage, allowing for personalized multidisciplinary specialized interventions that include pharmacologic therapies and additional supportive care measures. The aim of this review is to summarize key areas of active clinical research and new developments in cGVHD therapeutic approaches, with focus on (1) preemptive therapy, (2) upfront therapy beyond corticosteroids, (3) treatment refractory cGVHD novel agents, role of combination therapies, and organ-specific approaches, and (4) challenges, gaps, and future directions.<\/jats:p>","DOI":"10.1097\/tp.0000000000005345","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:01:06Z","timestamp":1738886466000},"page":"e446-e454","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Chronic Graft-versus-host Disease, Part 2: Clinical Success and Roadmap to the Future"],"prefix":"10.1097","volume":"109","author":[{"given":"Najla","family":"El Jurdi","sequence":"first","affiliation":[{"name":"Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Blood and Marrow Transplant and Cellular Therapy, University of Minnesota, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Z.","family":"Pavletic","sequence":"additional","affiliation":[{"name":"Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"R1-20250821","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"R2-20250821","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the chronic GVHD consortium.","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"key":"R3-20250821","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood.2023022735","article-title":"Chronic graft-versus-host disease: unresolved complication or ancient history?","volume":"144","author":"Pidala","year":"2024","journal-title":"Blood"},{"key":"R4-20250821","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease.","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R5-20250821","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets.","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20250821","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Articles Lancet Haematol"},{"key":"R7-20250821","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor\u2013free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies.","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"key":"R8-20250821","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis.","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"R9-20250821","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"R10-20250821","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study.","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"R11-20250821","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease.","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"R12-20250821","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2023-186963","article-title":"Safety and efficacy of axatilimab at 3 different doses in patients with chronic graft-versus-host disease (AGAVE-201).","volume":"142","author":"Wolff","year":"2023","journal-title":"Blood"},{"key":"R13-20250821","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease.","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20250821","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.21.01755","article-title":"Naive T-cell depletion to prevent chronic graft-versus-host disease.","volume":"40","author":"Bleakley","year":"2022","journal-title":"J Clin Oncol"},{"key":"R15-20250821","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease.","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-20250821","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41571-020-0356-4","article-title":"Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.","volume":"17","author":"Blazar","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R17-20250821","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jtct.2021.03.029","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIb. The 2020 preemptive therapy working group report.","volume":"27","author":"Pidala","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R18-20250821","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 clinical implementation and early diagnosis working group report.","volume":"27","author":"Kitko","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R19-20250821","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease.","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"key":"R20-20250821","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease.","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"key":"R21-20250821","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease.","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood"},{"key":"R22-20250821","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.bbmt.2015.01.003","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 biomarker working group report.","volume":"21","author":"Paczesny","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R23-20250821","doi-asserted-by":"crossref","first-page":"e168575","DOI":"10.1172\/JCI168575","article-title":"Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death.","volume":"133","author":"Logan","year":"2023","journal-title":"J Clin Investig"},{"key":"R24-20250821","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1182\/bloodadvances.2022007715","article-title":"A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE\/PBMTC 1202 study.","volume":"7","author":"Cuvelier","year":"2023","journal-title":"Blood Adv"},{"key":"R25-20250821","doi-asserted-by":"crossref","first-page":"e0298026","DOI":"10.1371\/journal.pone.0298026","article-title":"Study protocol: close assessment and testing for chronic graft-vs.-host disease (CATCH).","volume":"19","author":"Pidala","year":"2024","journal-title":"PLoS One"},{"key":"R26-20250821","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3324\/haematol.2018.195123","article-title":"A phase II\/III randomized, multicenter trial of prednisone\/sirolimus versus prednisone\/sirolimus\/calcineurin inhibitor for the treatment of chronic graft- versus -host disease: BMT CTN 0801.","volume":"103","author":"Carpenter","year":"2018","journal-title":"Haematologica"},{"key":"R27-20250821","doi-asserted-by":"crossref","first-page":"707.e1","DOI":"10.1016\/j.jtct.2022.04.014","article-title":"Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease.","volume":"28","author":"Bell","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R28-20250821","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood.V72.2.546.546","article-title":"Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.","volume":"72","author":"Sullivan","year":"1988","journal-title":"Blood"},{"key":"R29-20250821","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood.V100.1.48","article-title":"Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.","volume":"100","author":"Koc","year":"2002","journal-title":"Blood"},{"key":"R30-20250821","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","article-title":"Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.","volume":"7","author":"Arora","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"R31-20250821","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V96.12.3995","article-title":"Thalidomide for treatment of patients with chronic graft-versus-host disease.","volume":"96","author":"Koc","year":"2000","journal-title":"Blood"},{"key":"R32-20250821","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.","volume":"113","author":"Martin","year":"2009","journal-title":"Blood"},{"key":"R33-20250821","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2011.05.016","article-title":"Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a children\u2019s oncology group study.","volume":"18","author":"Gilman","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R34-20250821","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2017-05-786137","article-title":"Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study.","volume":"130","author":"Malard","year":"2017","journal-title":"Blood"},{"key":"R35-20250821","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/bloodadvances.2021005552","article-title":"A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease.","volume":"6","author":"Lazaryan","year":"2022","journal-title":"Blood Adv"},{"key":"R36-20250821","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.bbmt.2014.06.040","article-title":"A phase ii study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.","volume":"20","author":"Herrera","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R37-20250821","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study.","volume":"41","author":"Miklos","year":"2023","journal-title":"J Clin Oncol"},{"key":"R38-20250821","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41409-024-02289-0","article-title":"Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study.","volume":"59","author":"Ayuk","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"R39-20250821","doi-asserted-by":"crossref","first-page":"679.e1","DOI":"10.1016\/j.jtct.2022.07.004","article-title":"High response rate and corticosteroid sparing with arsenic trioxide-based first-line therapy in chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","volume":"28","author":"Rongvaux-Ga\u00efda","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R40-20250821","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1182\/blood-2019-128586","article-title":"Trial in progress: a phase 3 study of itacitinib or placebo in combination with corticosteroids as initial treatment for chronic graft-versus-host disease (GRAVITAS-309).","volume":"134","author":"Im","year":"2019","journal-title":"Blood"},{"key":"R41-20250821","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1182\/bloodadvances.2021005286","article-title":"Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival.","volume":"5","author":"Pidala","year":"2021","journal-title":"Blood Adv"},{"key":"R42-20250821","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41409-022-01881-6","article-title":"Steroid-free first line treatment of moderate and severe chronic GVHD: a survey from the transplant complications working party of the EBMT.","volume":"58","author":"Moiseev","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"R43-20250821","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood-2018-04-785899","article-title":"How I treat refractory chronic graft-versus-host disease.","volume":"133","author":"Sarantopoulos","year":"2019","journal-title":"Blood"},{"key":"R44-20250821","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.17835","article-title":"The clinical landscape of chronic graft\u2010versus\u2010host disease management in 2021.","volume":"196","author":"Holtzman","year":"2022","journal-title":"Br J Haematol"},{"key":"R45-20250821","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/leu.2016.367","article-title":"Novel targets in the treatment of chronic graft-versus-host disease.","volume":"31","author":"Im","year":"2017","journal-title":"Leukemia"},{"key":"R46-20250821","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-140392","article-title":"Efficacy and safety of baricitinib in refractory chronic graft-versus-host disease (cGVHD): preliminary analysis results of a phase 1\/2 study.","volume":"136","author":"Holtzman","year":"2020","journal-title":"Blood"},{"key":"R47-20250821","doi-asserted-by":"crossref","first-page":"e0222944","DOI":"10.1371\/journal.pone.0222944","article-title":"Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.","volume":"14","author":"Singer","year":"2019","journal-title":"PLoS One"},{"key":"R48-20250821","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1073\/pnas.1712452115","article-title":"Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.","volume":"115","author":"Betts","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"R49-20250821","doi-asserted-by":"crossref","first-page":"eaai8269","DOI":"10.1126\/scitranslmed.aai8269","article-title":"Targeting aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.","volume":"9","author":"Betts","year":"2017","journal-title":"Sci Transl Med"},{"key":"R50-20250821","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/JEP.S150729","article-title":"Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.","volume":"10","author":"Al-Fayoumi","year":"2018","journal-title":"J Exp Pharmacol"},{"key":"R51-20250821","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood-2024-193191","article-title":"A phase II study to evaluate the efficacy and safety of pimicotinib (ABSK021) in chronic graft versus host disease (cGvHD) after 1 or more lines of systemic treatment.","volume":"144","author":"Mo","year":"2024","journal-title":"Blood"},{"key":"R52-20250821","doi-asserted-by":"crossref","first-page":"10505","DOI":"10.1182\/blood-2022-164659","article-title":"JAK\/Rock inhibitor TQ05105 for glucocorticoid-refractory or -dependent chronic graft-versus-host disease: preliminary analysis results of a phase 1b\/2 study.","volume":"140","author":"Zhao","year":"2022","journal-title":"Blood"},{"key":"R53-20250821","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/bloodadvances.2018029124","article-title":"Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.","volume":"3","author":"Belizaire","year":"2019","journal-title":"Blood Adv"},{"key":"R54-20250821","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41409-023-02165-3","article-title":"Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease.","volume":"59","author":"Pusic","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"R55-20250821","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/1744666X.2023.2152330","article-title":"A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.","volume":"19","author":"Salhotra","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"R56-20250821","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2024-204703","article-title":"JAK\/Rock inhibitor rovadicitinib for glucocorticoid-refractory or -dependent chronic graft-versus-host disease: updated results of multicenter, phase 1b\/2a trial.","volume":"144","author":"Zhao","year":"2024","journal-title":"Blood"},{"key":"R57-20250821","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2023-180954","article-title":"Safety and efficacy of human amniotic epithelial stem cells eye dropin ocular chronic graft-versus-host disease.","volume":"142","author":"Cheng","year":"2023","journal-title":"Blood"},{"key":"R58-20250821","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood-2023-186076","article-title":"Efficacy and safety of processed amniotic fluid (pAF) drops for the treatment of ocular chronic graft-versus-host disease.","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"key":"R59-20250821","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1078-0432.CCR-15-1443","article-title":"A randomized phase ii crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation.","volume":"22","author":"Arai","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R60-20250821","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbmt.2015.03.006","article-title":"Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.","volume":"21","author":"Baird","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R61-20250821","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2023-182198","article-title":"Topical ruxolitinib for chronic cutaneous GvHD: promising results of a phase 2 clinical trial.","volume":"142","author":"Markova","year":"2023","journal-title":"Blood"},{"key":"R62-20250821","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2022-156340","article-title":"Ruxolitinib for treatment of steroid refractory sclerotic chronic graft-versus-host disease (cGVHD): results of a multicenter phase ii trial.","volume":"140","author":"Bhatt","year":"2022","journal-title":"Blood"},{"key":"R63-20250821","doi-asserted-by":"crossref","first-page":"264.e1","DOI":"10.1016\/j.jtct.2022.01.021","article-title":"Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplantation and investigation into bronchiolitis obliterans syndrome pathogenesis.","volume":"28","author":"Williams","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R64-20250821","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","article-title":"Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation.","volume":"22","author":"Williams","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R65-20250821","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/bloodadvances.2024014000","article-title":"A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT.","volume":"9","author":"DeFilipp","year":"2025","journal-title":"Blood Adv"},{"key":"R66-20250821","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1182\/bloodadvances.2022008095","article-title":"Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.","volume":"6","author":"DeFilipp","year":"2022","journal-title":"Blood Adv"},{"key":"R67-20250821","doi-asserted-by":"crossref","first-page":"1045168","DOI":"10.3389\/fimmu.2022.1045168","article-title":"Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease.","volume":"13","author":"Doglio","year":"2022","journal-title":"Front Immunol"},{"key":"R68-20250821","doi-asserted-by":"crossref","first-page":"959658","DOI":"10.3389\/fimmu.2022.959658","article-title":"Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.","volume":"13","author":"Stenger","year":"2022","journal-title":"Front Immunol"},{"key":"R69-20250821","doi-asserted-by":"crossref","first-page":"9676","DOI":"10.3390\/ijms22189676","article-title":"Regulatory T cell therapy of graft-versus-host disease: advances and challenges.","volume":"22","author":"Hefazi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R70-20250821","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1182\/bloodadvances.2021006625","article-title":"A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.","volume":"6","author":"Whangbo","year":"2022","journal-title":"Blood Adv"},{"key":"R71-20250821","doi-asserted-by":"crossref","first-page":"e160674","DOI":"10.1172\/jci.insight.160674","article-title":"Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses.","volume":"7","author":"Bolivar-Wagers","year":"2022","journal-title":"JCI Insight"},{"key":"R72-20250821","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/1078-0432.CCR-22-2837","article-title":"Human effectors of acute and chronic GVHD overexpress CD83 and predict mortality.","volume":"29","author":"Holtan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R73-20250821","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1172\/JCI135754","article-title":"Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.","volume":"130","author":"Shrestha","year":"2020","journal-title":"J Clin Invest"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T14:07:34Z","timestamp":1755785254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005345","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}